AbbVie Prepares Large Bond Sale -- Update
November 12 2019 - 3:34PM
Dow Jones News
By Sam Goldfarb
AbbVie Inc. is set Tuesday to sell $30 billion of bonds to help
fund its acquisition of Allergan PLC, taking advantage of
investors' strong demand for higher-quality business debt to bring
one of the largest corporate-bond sales on record.
Like other investment-grade companies that have completed large
bond sales in recent years, AbbVie was having little trouble
selling its debt. After holding calls with investors last week, the
drugmaker is poised to issue 10 different bonds with maturities
ranging from 1 1/2 years to 30 years.
Once AbbVie's bonds are allocated to investors, it will be the
fourth-largest investment-grade bond sale on record, exceeding
Comcast Corp.'s $27 billion sale in October of last year, according
to Dealogic.
For AbbVie, buying Allergan would give it a dominant position in
the $8 billion-plus market for beauty drugs, such as Botox, as it
attempts to diversify beyond Humira, its top-selling
rheumatoid-arthritis drug.
After the acquisition, the company's ratio of net debt to
earnings before interest, taxes, depreciation and amortization is
expected to almost double to 3.4 times, according to the research
firm CreditSights. The company, though, is hoping to bring that
ratio down to 2.5 times by the end of 2021 by using free cash flow
to pay down around $15 billion to $18 billion of debt.
In their first offer to investors Tuesday, banks proposed a
yield on AbbVie's new 10-year notes that would be 1.5 percentage
points above the comparable U.S. Treasury yield, investors said.
That was later lowered to 1.35 percentage points and ultimately
finalized at 1.30 percentage points.
By comparison, the company's existing bonds due in 2028 recently
traded at a 1.27 percentage-point spread to Treasurys, according to
CreditSights.
In recent trading, the yield on the benchmark 10-year U.S.
Treasury note was 1.922%, according to Tradeweb, compared with
1.930% Friday. The bond market was closed Monday for Veterans
Day.
Even with a recent increase in Treasury yields, it remains a
favorable borrowing environment for most companies. The average
U.S. investment-grade corporate-bond yield was 3.0% Friday, up from
around 2.8% in early October but still down from 4% in January,
according to Bloomberg Barclays data.
So far this year, companies have sold around $1.25 trillion of
investment-grade corporate bonds in the U.S. market, according to
Dealogic. That is a little more than were sold at this point last
year, though off the record-setting pace from two years ago.
Write to Sam Goldfarb at sam.goldfarb@wsj.com
(END) Dow Jones Newswires
November 12, 2019 15:19 ET (20:19 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Sep 2023 to Sep 2024